邱海波

一、基本情况

中山大学肿瘤医院胃外科主诊教授、主任医师、博士生导师，曾作为联合培养博士生留学于哈佛医学院。擅长胃肠肿瘤外科治疗，尤其是腹腔镜、机器人微创手术，曾多次在全国胃癌手术视频大赛获奖。主持国家自然基金、广东省自然科学基金等科研项目，以第一/通讯作者在Cancer Commun, Cancer Res, JECCR等杂志发表了SCI论文40余篇。在ASCO 2024年会、ESMO 2024年会做口头汇报。中国抗癌协会胃肠间质瘤青年委员会副主任委员，CSCO胃肠间质瘤、青年委员会专家委员会常委，CSCO翻译小组副组长并担任CSCO年会、BOA大会同声传译。《癌症》、《JCO》中文版等杂志编委。荣获CSCO 35 under 35全国最具潜力肿瘤医生奖项。获得羊城好医生、岭南好医生和广州实力中青年医生等称号。

门诊时间：周一上午、周四上午（越秀院区）；周一下午（黄埔院区）。

二、教育及工作经历

教育经历

2010.10－2012.09  哈佛大学医学院 联合培养博士生

2009.09－2013.06  中山大学 肿瘤学 博士

2006.09－2009.06  中山大学 肿瘤学 硕士

2001.09－2006.06  广州医学院 临床医学 本科

工作经历

2024.01-至今      中山大学肿瘤防治中心 胃外科 主任医师

2018.01-2023.12   中山大学肿瘤防治中心 胃外科 副主任医师

2016.01-2017.12   中山大学肿瘤防治中心 胃外科 主治医师

2013.08-2015.12   中山大学肿瘤防治中心 胃胰科 医师

三、学术兼职

中国抗癌协会胃肠间质瘤青年委员会 副主任委员

CSCO 胃肠间质瘤专家委员会 常务委员

CSCO 青年专家委员会 常务委员

四、主持科研项目

国家自然青年科学基金项目，81602061，JUN/Cyclin D1通路在胃肠间质瘤对伊马替尼耐药的作用及机制研究，2017/01-2019/12，主持。

广东省自然科学基金，面上项目，SALL1基因突变导致胃癌早发及腹膜转移的现象与机制 ，2022/01-2024/12，主持。

国家自然科学基金面上项目，81372474、《抑制PREX2逆转胃肠道间质瘤对酪氨酸激酶抑制剂耐药的研究》、2014/01-2017/12，第二参与人。

国家自然青年科学基金项目，81602143，TACC3介导肝癌射频消融治疗后转移复发的机制与干预策略，2017/01-2019/12，第二参与人。

五、代表性论著

Haibo Qiu, Sumei Cao , Ruihua Xu , Cancer incidence, mortality, and burden in China: a time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2021, Cancer Communications. 2021 Oct;41(10):1037-1048.

Xiayao Diao, Yudong Ling, Yi Zeng, Yueqian Wu, Chao Guo, Yukai Jin, Xiaojiang Chen, Shoucheng Feng, Jianrong Guo, Chao Ding, Feiyu Diao, Zhicheng Du, Shanqing Li, Haibo Qiu*. Physical activity and cancer risk: a dose-response analysis for the Global Burden of Disease Study 2019. Cancer Communications. 2023 Nov;43(11):1229-1243.

Haibo Qiu, Xu Zhang, Jiali Qi, Jiangwen Zhang, Yin Tong, Lei Li , Li Fu, Yan-Ru Qin, Xinyuan Guan, Liyi Zhang. Identification and characterization of FGFR2+hematopoietic stem cell-derived fibrocytes as precursors of cancer-associated fibroblasts induced by esophageal squamous cell carcinoma. J Exp Clin Cancer Res. 2022 Aug 8;41(1):240. 

Chen W#, Kuang Y#, Qiu HB#, Cao Z, Tu Y, Sheng Q, Eilers G, He Q, Li HL, Zhu M, Wang Y, Zhang R, Wu Y1, Meng F, Fletcher JA, Ou WB. Dual Targeting of Insulin Receptor and KIT in Imatinib-Resistant Gastrointestinal Stromal Tumors. Cancer Res. 2017 Sep 15;77(18):5107-5117. 

Li J#, Zhang J#, Zhang Y#, Qiu HB#, Zhou Y, Zhou Y, Zhang X, Zhou Y, Zhu Y, Li Y, Wang M, Shen K, Tao K, Wu X, Wang H, Zhang B, Ling J, Ye Y, Wu X, Qu H, Ma Y, Jiao X, Zheng H, Jin J, Liu Z, Tan M, Fang Y, Zhang P, Zhang N, Lei C, Cai Z, Liang B, Peng Z, Huang Z, Dong J, Shen L. Efficacy and safety of ripretinib vs. sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: A phase 2, multicenter, randomized, open-label study in China. Eur J Cancer. 2024 Jan:196:113439.

Haibo Qiu. Complete cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastases: results of a propensity score matching analysis from France. Cancer Communications.2019 Aug 8;39(1):45.

Haibo Qiu. Safety and efficacy of toripalimab in advanced gastric cancer: A new clinical trial bringing hope for immunotherapy in gastric cancer. Cancer Communications. 2020;40:194–196.

Jianrong Guo, Shoucheng Feng, Hong Liu, Zhuopeng Chen, Chao Ding, Yukai Jin, Xiaojiang Chen, Yudong Ling, Yi Zeng, Hao Long,and Haibo Qiu*. TRIM6: An Upregulated Biomarker with Prognostic Significance and Immune Correlations in Gliomas. Biomolecules2023,13,1298.

Jianrong Guo, Shoucheng Feng, Hong Yu, Biyi Ou, Dan Jiang, Wei Zhuang, Chao Ding, Xiaojiang Chen, Miaoquan Zhang, Yudong Ling, Yi Zeng and Haibo Qiu*. Transcriptomic study of gastrointestinal stromal tumors with liver metastasis.Front. Genet. 14:1007135. doi: 10.3389/fgene.2023.1007135

Miaoquan Zhang #, Chao Ding# , Lin Xu# , Biyi Ou , Shoucheng Feng, Guoqiang Wang, Wei Wang , Yao Liang, Yingbo Chen, Zhiwei Zhou, Haibo Qiu*. Comparison of a Tumor-Ratio-Metastasis Staging System and the 8th AJCC TNM Staging System for Gastric Cancer. Front Oncol. 2021 Jul 8;11:595421.

Miaoquan Zhang # , Chao Ding # , Lin Xu # , Shoucheng Feng , Yudong Ling, Jianrong Guo, Yao Liang, Zhiwei Zhou, Yingbo Chen, Haibo Qiu*.A nomogram to predict risk of lymph node metastasis in early gastric cancer. Sci Rep. 2021 Nov 24;11(1):22873.

Zhang LY#, Wu JL#, Qiu HB#, Dong SS, Zhu YH, Lee VH, Qin YR, Li Y, Chen J, Liu HB, Bi J, Ma S, Guan XY, Fu L. PSCA acts as a tumor suppressor by facilitating the nuclear translocation of RB1CC1 in esophageal squamous cell carcinoma. Carcinogenesis. 2016 Mar;37(3):320-332. 

Wei Zhuang#, Jing‐Dun Xie#, Shan Zhou, Zhi‐Wei Zhou, Yi Zhou, Xiao‐Wei Sun, Xiu‐Hong Yuan, Min Huang, Si Liu, Shuang Xin, Qi‐Biao Su, HaiBo Qiu*, Xue‐Ding Wang*. Can therapeutic drug monitoring increase the safety of Imatinib in GIST patients? Cancer Med. 2018 Feb; 7(2): 317–324.

Qiu HB#, Zhuang W#, Wu T, Xin S, Lin CZ, Ruan HL, Zhu X, Huang M, Li JL, Hou XY, Zhou ZW, Wang XD. Imatinib-induced ophthalmological side-effects in GIST patients are associated with the variations of EGFR, SLC22A1, SLC22A5 and ABCB1. Pharmacogenomics J. 2018 May 22;18(3):460-466.

国际大会报告

Haibo Qiu, Zhiwei Zhou, Ye Zhou,Jie Chen,Xiangbin Wan,Ning Li, Kaixiong Tao, Yong Li, Xin Wu, Zi Chen,Lihui Liu, Chen Yang, Lichuang Men, Hengbang Wang, Eric Liang,Cunlin Wang,Lixin Jiang, Dajun Yang, Yifan Zhai,and Ruihua Xu. Updated efficacy results of olverembatinib (HQP1351) in patients with tyrosine kinase inhibitor (TKI)-resistant succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors (GIST) and paraganglioma. ASCO annual meeting, Oral Presentation, June 2024.Chicago, US.

Haibo Qiu, Zhiwei Zhou, Ye Zhou, XiangBin Wan, Kaixiong Tao, Yong Li, Xin Wu, Lihui Liu, Zi Chen, Lichuang Men, Zhiyan Liang, Ming Lu, Lixin Jiang, Dajun Yang, Yifan Zhai，Rui-hua Xu.Promising antitumor activity of olverembatinib (HQP1351) in patients (pts) with tyrosine kinase inhibitor- (TKI-) resistant succinate dehydrogenase- (SDH-) deficient gastrointestinal stromal tumor (GIST). ASCO, Poster discussion, June 2022.Chicago, US. 

Haibo Qiu. Palliative Surgical resection for patients with the advanced Gastrointestinal Stromal Tumor. International Gastric Cancer Conference. Oral Presentation. April 2017 Beijing, China.

论文摘要

Haibo Qiu, Zhongguo Zhou, Xingyu Feng, Xiaowei Sun, Yingbo Chen, Yuanxiang Guan, Dazhi Xu, Yuanfang Li, Wei Li, Youqing Zhan, Rui-hua Xu, Zhiwei Zhou. Results of long-term follow-up for patients with advanced gastrointestinal stromal tumor underwent palliative surgery after tyrosine kinase inhibitors therapy. Journal of Clinical Oncology 34, no. 15_suppl   

Haibo Qiu, Wei Zhuang, Ting Wu, Min Huang, Zhiwei Zhou, Xueding Wang. Next generation sequencing (NGS) in wild type GISTs. Journal of Clinical Oncology 35, no. 15_suppl 

主编或编写专著

CSCO胃肠间质瘤诊治指南, 中国临床肿瘤学会，2023年，编委。

胃肠间质瘤规范化外科治疗中国专家共识，中国医师协会，2018年，编委。

六、 获奖及荣誉

2022 获羊城好医生，岭南好医生，广州实力中青年医生等称号。

2021 大中华区胃癌手术视频比赛 总决赛 冠军

2017 CSCO最具潜力肿瘤医生奖

2017 GIST-TOUR 全国研究设计比赛 冠军

2012 获教育部优秀研究生学金

2012 中山大学优秀博士生

更新时间：2024.10.12